With over three years of experience in the medical communications business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical research.
NeuroVive Pharmaceutical AB has completed recruitment of healthy subjects for the second part of an ongoing Phase 1a/b study testing its oral treatment candidate KL1333 for primary mitochondrial disease. The ... Read more
Researchers in Spain have made a discovery that has important implications for treatment strategies to prevent mitochondrial diseases from being passed from mother to child. Specifically, they found that the ... Read more
A retrospective study of nucleoside therapy for treating the very rare mitochondrial disorder thymidine kinase 2 deficiency (TK2d) has shown positive results, including improved survival rates among children and adults with ... Read more
The U.S. Department of Defense (DoD) has awarded a $4 million, three-year grant to the Children’s Hospital of Philadelphia (CHOP) to advance NeuroVive Pharmaceutical AB‘s NVP015 program for genetic mitochondrial ... Read more
BridgeBio Pharma has entered into an exclusive licensing agreement with NeuroVive Pharmaceutical AB for the development of a subset of chemical compounds under NeuroVive’s NVP015 program. The goal is to further develop ... Read more
The cell’s powerhouse and garbage disposal — two distinct cell structures known as mitochondria and lysosome, respectively — regulate their function by communicating directly with each other within the cell, a ... Read more
Stealth BioTherapeutics‘ investigational medicine elamipretide, formerly known as Bendavia, has been granted orphan drug status by the U.S. Food and Drug Administration’s (FDA) for the treatment of primary mitochondrial myopathy (PMM). Stealth specializes ... Read more